Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Natural History of C3 Glomerulopathy and Immune Complex-Associated Membranoproliferative Glomerulonephritis in Children.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm With Updated Criteria.

American journal of medical genetics. Part A·2026
Same author

Reliability of ultrasound imaging of erector spinae and gluteus medius muscle function using linear regression estimation of contraction.

Journal of back and musculoskeletal rehabilitation·2026
Same author

Correction: Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies.

Trials·2026
Same author

Defining key criteria for microhaplotype locus selection in forensic genetics: Progress and recommendations by the Microhaplotype Working Group.

Forensic science international. Genetics·2026
Same author

Biomarkers of Exposure to Tobacco-Related Toxicants among Adult Nicotine Pouch Users.

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco·2025
Same journal

A Patient's Perspective on Arteriovenous Fistula Care and Far-Infrared Radiation Arteriovenous Fistula Therapy.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

A Beacon of Hope: Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

Sequential Biomarker Testing in Kidney Transplant Surveillance: How Far Does One Step at a Time Take Us?

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

The Predicting Risk of Cardiovascular Disease Event Equation Meets CKD.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

Muscle Cramp Rate, Severity and Burden in Maintenance Hemodialysis Patients: A Yearlong Multicenter Quality Improvement Initiative.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

From Risk Determinants to Clinical Action: Understanding and Implementing the Cardiovascular Kidney Metabolic Syndrome Framework.

Clinical journal of the American Society of Nephrology : CJASN·2026
See all related articles

Related Experiment Video

Updated: Jun 22, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

Hepcidin for clinicians.

Brian Young1, Joshua Zaritsky

  • 1Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA.

Clinical Journal of the American Society of Nephrology : CJASN
|June 27, 2009
PubMed
Summary
This summary is machine-generated.

Hepcidin, a key regulator of iron, plays a major role in treating anemia of chronic kidney disease (CKD) and resistance to erythropoiesis-stimulating agents (ESAs). Understanding hepcidin is crucial for effective anemia management in CKD patients.

Related Experiment Videos

Last Updated: Jun 22, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

Area of Science:

  • Nephrology
  • Iron Metabolism
  • Biochemistry

Background:

  • Anemia of chronic kidney disease (CKD) is often resistant to erythropoiesis-stimulating agents (ESAs).
  • Iron deficiency and inflammation contribute to ESA resistance, but are hard to detect with current markers.
  • Hepcidin, a liver-produced peptide, is a key regulator of iron homeostasis.

Purpose of the Study:

  • To discuss the biologic actions and regulation of hepcidin.
  • To review studies on hepcidin in CKD.
  • To explore hepcidin's role in anemia of CKD and ESA resistance.

Main Methods:

  • Review of existing literature on hepcidin.
  • Discussion of hepcidin's role in iron metabolism.
  • Analysis of hepcidin's regulation and function in CKD.

Main Results:

  • Hepcidin regulates iron absorption and release by controlling ferroportin.
  • Altered hepcidin metabolism in CKD may affect iron availability.
  • Hepcidin is implicated in both anemia of CKD and ESA resistance.

Conclusions:

  • Hepcidin is a critical factor in the anemia of CKD.
  • Hepcidin dysregulation contributes to ESA resistance.
  • Further research into hepcidin is vital for managing CKD anemia.